Association of anaplastic lymphoma kinase variants and alterations with ensartinib response duration in non ‐small cell lung cancer

ConclusionsOur study showed that secondary ALK alterations were adversely associated with ensartinib efficacy, and that ALK variants might not correlate with PFS. The quantitative radiomic signature provided added prognostic prediction value to the clinicopathological features.

Source: Thoracic Cancer - July 20, 2021 Category: Cancer & Oncology Authors: Donghui Hou, Xiaomin Zheng, Wei Song, Xiaoqing Liu, Sicong Wang, Lina Zhou, Xiuli Tao, Lv Lv, Qi Sun, Yujing Jin, Zewei Zhang, Lieming Ding, Ning Wu, Shijun Zhao Tags: ORIGINAL ARTICLE Source Type: research